Association of *HMGA2* Polymorphisms with Glioma Susceptibility in Chinese Children

Jingying Zhou¹
 Pan Wang¹
 Ran Zhang²
 Xiaokai Huang¹
 Hanqi Dai¹
 Li Yuan³
 Jichen Ruan¹

¹Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, People's Republic of China; ²Sydney School of Public Health, The University of Sydney, Camperdown, Sydney, NSW, 2006, Australia; ³Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, People's Republic of China

Background: Glioma is a malignant central nervous system tumor in children, with poor outcomes and prognosis. *HMGA2* is a proto-oncogene with increased expression in various malignancies.

Methods: We explored the association of *HMGA2* polymorphisms with glioma susceptibility in Chinese children using a case-control study (191 cases, 248 controls). *HMGA2* single nucleotide polymorphisms (rs6581658 A>G; rs8756 A>C; rs968697 T>C) were genotyped using PCR-based TaqMan.

Results: Increased glioma susceptibility was associated with rs6581658 A>G; AG (adjusted odds ratio (OR) = 1.71, 95% confidence interval (CI) = 1.13–2.58, *P* = 0.010) or GG (adjusted OR = 3.12, 95% CI = 1.26–7.74, *P* = 0.014) genotype carriers had significantly raised glioma risk compared with AA genotype carriers. The rs6581658 AG/GG (adjusted OR = 1.85, 95% CI = 1.25–2.73, *P* = 0.002) and AA/GG (adjusted OR = 2.58, 95% CI = 1.05–6.33, *P* = 0.038) genotypes were associated with an increased risk of glioma relative to the AA genotype. Subjects with 2–3 risk genotypes had a significantly elevated risk (adjusted OR = 1.93, 95% CI = 1.31–2.84, *P* = 0.001) relative to those with 0–1 risk genotype.

Conclusion: *HMGA2* rs6581658 A>G is associated with glioma susceptibility in Chinese children.

Keywords: *HMGA2*, polymorphism, susceptibility, glioma

Introduction

Glioma is an intracranial tumor, that can be categorized into subtypes, as follows: diffuse astrocytic and oligodendroglial, other astrocytic, ependymal, or other glioma.¹ Brain cancer is the leading cause of cancer deaths in children.² From 2001 to 2010, the incidence of intracranial and intraspinal tumors in British children under the age of 15 was 1/1678, among which astrocytoma accounted for 40%.³ The most common type of glioma in children is pilocytic astrocytoma. The 5-year survival rates for patients with many glioma subtypes are relatively high; however, the 5-year survival rate for specific types of glioma, such as glioblastoma (GBM), is only 14%.³ Glioma occurrence can be influenced by ionizing radiation, allergic disease, and gene mutation. Although glioma can currently be treated using surgery, radiotherapy, and chemotherapy, its heterogeneity and invasiveness make it prone to drug resistance and recurrence. Hence, future prospects for treatment of pediatric brain tumors tend more towards molecularly targeted therapy.^{4,5} Some genetic loci have been identified as associated with increased susceptibility to adult glioma, including *RTEL1*,⁶ *CDKN2A/B*,⁶ *PHLDB1*,⁶ *CCDC26*⁷ and *TERT*,⁷ however, these risk loci cannot fully explain the molecular genetic contribution to glioma. Further,

Correspondence: Jichen Ruan
 Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, Zhejiang, People's Republic of China
 Email delcruanjichen@163.com

Li Yuan
 Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, 510623, Guangdong, People's Republic of China
 Email lizyklarck@126.com

pediatric glioma has molecular and genetic differences from adult glioma.^{8,9} Therefore, identification of suitable gene markers for application in pediatric glioma is increasingly important, and the influence of other genes on susceptibility to pediatric glioma warrants further study.

HMGA2 is a 160 kb gene located on chromosome 12. As an architectural transcription factor, *HMGA2* has three AT-hook domains that interact with AT-rich sequences in DNA minor grooves, leading to alteration of the chromatin architecture and modulation of the maintenance and assembly of enhancer complexes.¹⁰ Although it is widely expressed in embryos, *HMGA2* is not present in adults, except in stem cells. Further, it is expressed in tumor cells, including colon cancer,¹¹ lung cancer,¹² liver cancer,¹³ thyroid tumor¹⁴ and prostate cancer.¹⁵ Therefore, *HMGA2* is considered to be a proto-oncogene that promotes the occurrence and development of tumors.¹⁶

HMGA2 expression is also increased in glioma.¹⁷ Genomic single nucleotide polymorphisms (SNPs) are closely related to disease susceptibility and prognosis;^{18,19} however, few studies have focused on the relationship between *HMGA2* SNPs and glioma. Our research explored the association of *HMGA2* polymorphisms with glioma susceptibility in Chinese children.

Materials and Methods

Patients and Controls

We selected participants from Guangzhou and Wenzhou, including 191 cases histopathologically diagnosed with glioma and a control group of 248 healthy children with no family history of cancer, who were matched for sex and age with those in the experimental group. The Institutional Review Board of two hospitals approved the study protocol (the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Guangzhou Women and Children's Medical Center). In accordance with the Declaration of Helsinki, all subjects or their guardians signed informed consent forms.

Polymorphism Selection and Genotyping

We investigated the potentially functional *HMGA2* polymorphisms and selected three *HMGA2* polymorphisms (rs6581658 A>G, rs8756 A>C, and rs968697 T>C) based on data obtained in the SNPinfo (<https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html>) and dbSNP database (<https://www.ncbi.nlm.nih.gov/snp/>). The rs8756 A>C was located in 3' untranslated region (UTR) of the *HMGA2* gene. It

may affect microRNA binding affinity and subsequently affects expression and stabilization of *HMGA2* gene. The rs6581658 A>G and rs968697 T>C were located in the 5' near gene region. Binding of transcription factors may be affected, which may influence the transcription of *HMGA2*. There was no significant linkage disequilibrium among the selected SNPs ($r^2 < 0.8$). All SNPs had minor allele frequencies > 5% and potential biological function. Genomic DNA was extracted from venous blood samples and genotyped by TaqMan real-time PCR. The principle of tagging SNP selection and the genotyping methods used were described in our previous publications.^{20–22}

Statistical Analysis

Distributions of demographic characteristics and genotype frequencies in both groups and appropriate intergroup comparisons were assessed by chi-square analysis. Hardy-Weinberg equilibrium (HWE) was evaluated in the control group using the goodness-of-fit chi-square test, whereas the association between the *HMGA2* SNPs and glioma susceptibility was assessed by univariate and multivariate unconditional logistic regression analysis, to generate odds ratio (OR) and 95% confidence interval (CI) values. We performed stratified analysis, according to age, sex, glioma subtype, and clinical grade. The criterion for statistical significance was $P < 0.05$. All two-sided statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).

Results

Participant Characteristics

The general characteristics of subjects are presented in Table 1. All participants were < 168 months old, with mean ages of patients ($n = 191$) of 62.74 ± 47.28 months and of controls ($n = 248$) of 53.90 ± 33.47 months. The majority of tumors were of the astrocytic subtype. In the case group, 57.59%, 19.90%, 8.90%, and 13.09% of patients were at clinical grades I–IV, respectively; clinical grade data were unavailable for 0.52% of patients.

Relationship Between *HMGA2* SNPs and Glioma Risk

The detailed results are shown in Table 2. In analysis of the entire cohort, carriers of the rs6581658 AG genotype (adjusted OR = 1.71, 95% CI = 1.13–2.58, $P = 0.010$) or GG genotype (adjusted OR = 3.12, 95% CI = 1.26–7.74, $P = 0.014$) were found to have a significantly elevated risk

Table I Frequency Distribution of Selected Variables in Glioma Patients and Cancer-Free Controls

Variables	Cases (N=191)		Controls (N=248)		P ^a
	No.	%	No.	%	
Age range, month	2.60–168.00		4.00–168.00		0.997
Mean ± SD	62.74 ± 47.28		53.90 ± 33.47		
<60	97	50.79	126	50.81	
≥60	94	49.21	122	49.19	
Gender					0.329
Female	89	46.60	104	41.94	
Male	102	53.40	144	58.06	
Subtypes					
Astrocytic tumors	136	71.20	/	/	
Ependymoma	33	17.28	/	/	
Neuronal and mixed neutonal-glia tumors	14	7.33	/	/	
Embryonal tumors	7	3.66	/	/	
NA	1	0.52	/	/	
WHO grades					
I	110	57.59	/	/	
II	38	19.90	/	/	
III	17	8.90	/	/	
IV	25	13.09	/	/	
NA	1	0.52	/	/	

Note: ^aTwo-sided χ^2 test for distributions between glioma patients and cancer-free controls.

Abbreviations: SD, standard deviation; NA, not available.

of developing glioma compared with those with the AA genotype. Further investigation indicated that subjects with rs6581658 AG/GG (adjusted OR = 1.85, 95% CI = 1.25–2.73, $P = 0.002$) or AA/GG (adjusted OR = 2.58, 95% CI = 1.05–6.33, $P = 0.038$) genotypes had an increased risk of glioma relative to those with AA genotype. Moreover, we observed that individuals with 2–3 risk genotypes had a significantly elevated risk relative to those with 0–1 risk genotype (adjusted OR = 1.93, 95% CI = 1.31–2.84, $P = 0.001$).

Stratification Analysis

We next explored the effects of rs6581658 genotype and joint risk genotypes on glioma susceptibility following further stratification, according to age, sex, tumor subtype, and clinical grade. The results are presented in Table 3. The rs6581658 AG/GG genotypes significantly increased glioma susceptibility in children > 60 months old (adjusted OR = 2.07, 95% CI = 1.19–3.59, $P = 0.010$), males

(adjusted OR = 2.07, 95% CI = 1.23–3.50, $P = 0.007$), patients with astrocytic tumor subtype (adjusted OR = 1.70, 95% CI = 1.10–2.64, $P = 0.017$), and those with ependymoma subtype (adjusted OR = 2.47, 95% CI = 1.17–5.21, $P = 0.018$), clinical grade I (adjusted OR = 1.77, 95% CI = 1.11–2.81, $P = 0.016$), grade IV (adjusted OR = 3.16, 95% CI = 1.29–7.69, $P = 0.012$), grade I+II (adjusted OR = 1.67, 95% CI = 1.10–2.55, $P = 0.017$) and grade III+IV (adjusted OR = 2.72, 95% CI = 1.38–5.33, $P = 0.004$).

On analysis of combination risk genotypes, we found that subjects with 2–3 risk genotypes had an increased glioma risk relative to those with 0–1 risk genotype, among the following subgroups: age < 60 months (adjusted OR = 1.97, 95% CI = 1.15–3.38, $P = 0.014$), age ≥ 60 months (adjusted OR = 2.01, 95% CI = 1.15–3.51, $P = 0.014$), males (adjusted OR = 1.70, 95% CI = 1.01–2.86, $P = 0.046$), patients with astrocytic tumors (adjusted OR = 1.89, 95% CI = 1.22–2.92, $P = 0.004$), patients with ependymoma (adjusted OR = 2.18, 95% CI = 1.01–4.68, $P = 0.046$) and children at clinical grade I (adjusted OR = 1.76, 95% CI = 1.10–2.79, $P = 0.017$), grade III (adjusted OR = 4.11, 95% CI = 1.29–13.15, $P = 0.017$), grade I+II (adjusted OR = 1.74, 95% CI = 1.15–2.64, $P = 0.009$), and grade III+IV (adjusted OR = 3.00, 95% CI = 1.43–6.29, $P = 0.004$).

Discussion

Here, we studied the association of *HMGA2* polymorphisms with glioma susceptibility in Chinese children. The relationship between these three gene polymorphisms and glioma susceptibility has not been studied previously. We found that rs6581658 AG/GG was associated with a significantly increased risk of susceptibility to glioma.

HMGA2 promotes cancer progression through several functions: promoting cell proliferation and metastasis, influencing the cell cycle, inhibiting apoptosis, and conferring stem cell characteristics.²³ *HMGA2* overexpression can promote the migration and invasion of pancreatic cancer cells,²⁴ and *HMGA2* can inhibit apoptosis and promote cell proliferation in breast cancer, as well as conferring stem cell-like features, whereas knocking out *HMGA2* led to cell cycle arrest at G2/M, reducing tumor invasiveness.²⁵ Further, *HMGA2* overexpression reduced the sensitivity of pancreatic cancer cells to the standard first-line drug, gemcitabine.²⁶ *HMGA2* is regulated as a downstream target of many miRNAs and is involved in progression of various tumors. *HMGA2* can also promote epithelial-mesenchymal transition of esophageal squamous

Table 2 *HMGA2* Gene Polymorphisms and Glioma Susceptibility in Chinese Children

Genotype	Cases (N=191)	Controls (N=248)	P ^a	Crude OR (95% CI)	P	Adjusted OR (95% CI) ^b	P ^b
rs6581658 A>G (HWE=0.933)							
AA	101 (52.88)	168 (67.74)		1.00		1.00	
AG	76 (39.79)	72 (29.03)		1.76 (1.17–2.64)	0.007	1.71 (1.13–2.58)	0.010
GG	14 (7.33)	8 (3.23)		2.91 (1.18–7.18)	0.020	3.12 (1.26–7.74)	0.014
Additive			0.0008	1.73 (1.25–2.40)	0.0009	1.73 (1.25–2.41)	0.001
Dominant	90 (47.12)	80 (32.26)	0.002	1.87 (1.27–2.76)	0.002	1.85 (1.25–2.73)	0.002
Recessive	177 (92.67)	240 (96.77)	0.051	2.37 (0.97–5.78)	0.057	2.58 (1.05–6.33)	0.038
rs8756 A>C (HWE=0.513)							
AA	161 (84.29)	214 (86.29)		1.00		1.00	
AC	29 (15.18)	32 (12.90)		1.21 (0.70–2.07)	0.501	1.25 (0.72–2.16)	0.427
CC	1 (0.52)	2 (0.81)		0.67 (0.06–7.39)	0.740	0.62 (0.06–6.88)	0.693
Additive			0.638	1.13 (0.69–1.85)	0.638	1.15 (0.70–1.90)	0.582
Dominant	30 (15.71)	34 (13.71)	0.557	1.17 (0.69–2.00)	0.557	1.21 (0.71–2.07)	0.490
Recessive	190 (99.48)	246 (99.19)	0.721	0.65 (0.06–7.19)	0.723	0.60 (0.05–6.68)	0.676
rs968697 T>C (HWE=0.707)							
TT	141 (73.82)	191 (77.02)		1.00		1.00	
TC	47 (24.61)	54 (21.77)		1.18 (0.75–1.84)	0.471	1.17 (0.75–1.84)	0.492
CC	3 (1.57)	3 (1.21)		1.36 (0.27–6.81)	0.713	1.28 (0.25–6.51)	0.767
Additive			0.430	1.18 (0.79–1.76)	0.430	1.16 (0.78–1.74)	0.467
Dominant	50 (26.18)	57 (22.98)	0.440	1.19 (0.77–1.84)	0.440	1.18 (0.76–1.83)	0.469
Recessive	188 (98.43)	245 (98.79)	0.747	1.30 (0.26–6.53)	0.747	1.23 (0.24–6.25)	0.801
Combined effect of risk genotypes ^c							
0–1	69 (36.13)	131 (52.82)		1.00		1.00	
2–3	122 (63.87)	117 (47.18)	0.0005	1.98 (1.35–2.91)	0.0005	1.93 (1.31–2.84)	0.001

Notes: The results were in bold, if the 95% CI excluded 1 or p-values less than 0.05; ^a χ^2 test for genotype distributions between glioma patients and cancer-free controls;

^bAdjusted for age and gender; ^cRisk genotypes were carriers with rs6581658 AG/GG, rs8756 AC/AA, rs968697 TC/CC genotypes.

Abbreviations: OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.

cell carcinoma, which can be targeted by binding of *miR-490-3p* to its 3' untranslated region.²⁷ In addition, *HMGA2* can be regulated via the *miR-503-5p/HMGA2* and *miR-150-5p/HMGA2* axes, to promote the progression of gastric and breast cancers, respectively.^{28,29} *HMGA2* can also be targeted by *miR-493* to inhibit tongue squamous cell carcinoma.³⁰

In addition to the cancers mentioned above, *HMGA2* is also associated with glioma. *HMGA2* expression is up-regulated in glioma,³¹ which is associated with tumorigenicity, since increased *HMGA2* in vivo can promote the glioma growth, and the increased clonogenicity in vitro also supports the role of *HMGA2* in tumor initiation.³² Further, *HMGA2* expression, a target gene of *miR-107*, could be enhanced by the long non-coding RNA LINC00152 through regulation of *miR-107* expression and

promotion of glioma occurrence.³³ Moreover, *HMGA2* expression level is associated with glioma grade. Compared with diffuse astrocytoma, *HMGA2* expression is higher in glioblastoma multiforme and anaplastic astrocytoma³⁴ and increased *HMGA2* expression suggests worse prognosis. *HMGA2* is also associated with glioma malignant degree. In GBM cell lines, *HMGA2* increased GBM cell invasion, clonogenicity, and tumorigenicity.³² *HMGA2* may also activate *MMP2*, which can increase glioma invasion.³⁵ In contrast, *HMGA2* suppression inhibits glioma growth. *HMGA2* is suppressed by *let-7g-5p* and down-regulation of *HMGA2* expression can promote GBM tumor cell apoptosis and inhibit their invasion, indicating that *HMGA2* is a potential novel target gene in GBM.³⁶ In addition, *HMGA2* can be targeted by *miR-370-3p*, which inhibits glioma cell growth and

Table 3 Stratification Analysis of Risk Genotypes with Glioma Susceptibility

Variables	rs6581658		AOR (95% CI) ^a	P ^a	Risk Genotypes		AOR (95% CI) ^a	P ^a
	(Cases/Controls)				(Cases/Controls)			
	AA	AG/GG			0–1	2–3		
Age, month								
<60	55/87	42/39	1.72 (0.99–3.00)	0.054	37/69	60/57	1.97 (1.15–3.38)	0.014
≥60	46/81	48/41	2.07 (1.19–3.59)	0.010	32/62	62/60	2.01 (1.15–3.51)	0.014
Gender								
Females	50/71	39/33	1.60 (0.88–2.89)	0.123	31/58	58/46	2.26 (1.25–4.07)	0.007
Males	51/97	51/47	2.07 (1.23–3.50)	0.007	38/73	64/71	1.70 (1.01–2.86)	0.046
Subtypes								
Astrocytic tumors	74/168	62/80	1.70 (1.10–2.64)	0.017	49/131	87/117	1.89 (1.22–2.92)	0.004
Ependymoma	16/168	17/80	2.47 (1.17–5.21)	0.018	12/131	21/117	2.18 (1.01–4.68)	0.046
Neuronal and mixed	6/168	8/80	2.87 (0.95–8.64)	0.061	5/131	9/117	2.07 (0.67–6.43)	0.208
Embryonal tumors	4/168	3/80	1.59 (0.31–8.16)	0.577	2/131	5/117	1.83 (0.32–10.68)	0.500
Clinical stages								
I	59/168	51/80	1.77 (1.11–2.81)	0.016	42/131	68/117	1.76 (1.10–2.79)	0.017
II	23/168	15/80	1.36 (0.67–2.75)	0.390	15/131	23/117	1.71 (0.85–3.44)	0.134
III	8/168	9/80	2.56 (0.94–6.98)	0.066	4/131	13/117	4.11 (1.29–13.15)	0.017
IV	10/168	15/80	3.16 (1.29–7.69)	0.012	7/131	18/117	2.49 (0.97–6.39)	0.058
I+II	82/168	66/80	1.67 (1.10–2.55)	0.017	57/131	91/117	1.74 (1.15–2.64)	0.009
III+IV	18/168	24/80	2.72 (1.38–5.33)	0.004	11/131	31/117	3.00 (1.43–6.29)	0.004

Notes: The results were in bold, if the 95% CI excluded 1 or p-values less than 0.05; ^aAdjusted for age and gender, omitting the corresponding stratify factor.

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.

invasion³⁷ and is, therefore, a potential target for glioma therapy.

Many researchers have focused on the relationship between *HMGA2* gene SNPs and susceptibility to different conditions. For example, *HMGA2* SNPs are related to height. *HMGA2* rs1042725 influences height variability in European populations, and the association is more pronounced in individuals with small size for gestational age (SGA).³⁸ Further, *HMGA2* rs7968902 is significantly correlated with the height of the Japanese population.³⁹ We previously explored the effect of *HMGA2* SNPs on susceptibility to different diseases and found that *HMGA2* polymorphisms weakly influence Wilms tumor.⁴⁰ In addition, the *HMGA2* SNPs, rs8756A>C and rs968697T>C, are associated with lower susceptibility to neuroblastoma⁴¹ and hepatoblastoma,⁴² respectively.

This is the first study to investigate the relationship between *HMGA2* SNPs and glioma susceptibility. We found that the relationship is highly significant. Nevertheless, this study has limitations. First, the prevalence of glioma is low, and the sample size was

relatively moderate, which may affect the statistical power of the analysis. Second, we only selected three *HMGA2* SNPs, while other *HMGA2* SNPs may also be related to glioma susceptibility. Third, the sample was from Chinese children alone, therefore, the results may not be relevant to other populations. Fourth, this study was retrospective; therefore, selection bias cannot be avoided. Finally, environmental factors, which can also influence glioma susceptibility, were not taken into consideration.

Conclusion

We analyzed *HMGA2* SNPs and the risk of gliomas in the Chinese Han population. Our study is the first to identify a role for *HMGA2* gene polymorphisms in glioma susceptibility. The results contribute to understanding of glioma etiology; however, further studies with a larger sample size, increased representation of other ethnic groups, and that consider interactions between the environment, genetics, and other factors, are required.

Abbreviations

OR, odds ratio; CI, confidence interval; GBM, glioblastoma; SNP, genomic single nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium.

Ethics Approval and Informed Consent

The Institutional Review Board of two hospitals approved the study protocol (the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Guangzhou Women and Children's Medical Center). All subjects or their guardians signed informed consent forms.

Consent for Publication

Written informed consent for publication was obtained from all participants.

Acknowledgment

This study was supported by a grant from the National Natural Science Foundation of China (No: 81802346). The funder had no contribution to the research design, data acquisition and analysis, approval for publishing, or drafting the manuscript.

Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

- Malzkorn B, Reifenberger G. Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. *Curr Opin Oncol*. 2016;28(6):494–501. doi:10.1097/CCO.0000000000000327
- Hanz SZ, Adeuyan O, Lieberman G, Hennika T. Clinical trials using molecular stratification of pediatric brain tumors. *Transl Pediatr*. 2020;9(2):144–156. doi:10.21037/tp.2020.03.04
- Stiller CA, Bayne AM, Chakrabarty A, Kenny T, Chumas P. Incidence of childhood CNS tumours in Britain and variation in rates by definition of malignant behaviour: population-based study. *BMC Cancer*. 2019;19(1):139. doi:10.1186/s12885-019-5344-7
- Patel RR, Ramkissoon SH, Ross J, Weintraub L. Tumor mutational burden and driver mutations: characterizing the genomic landscape of pediatric brain tumors. *Pediatr Blood Cancer*. 2020;67(7):e28338. doi:10.1002/pbc.28338
- Cacciotti C, Fleming A, Ramaswamy V. Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy. *J Pathol*. 2020;251(3):249–261. doi:10.1002/path.5457
- Viana-Pereira M, Moreno DA, Linhares P, et al. Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients. *Mol Biol Rep*. 2020;47(2):877–886. doi:10.1007/s11033-019-05178-8
- Walsh KM, Rice T, Decker PA, et al. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. *Neuro Oncol*. 2013;15(8):1041–1047. doi:10.1093/neuonc/not051
- Collins KL, Pollack IF. Pediatric low-grade gliomas. *Cancers*. 2020;12(5):1152. doi:10.3390/cancers12051152
- Guerreiro Stucklin AS, Ryall S, Fukuoka K, et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. *Nat Commun*. 2019;10(1):4343. doi:10.1038/s41467-019-12187-5
- Huang YM, Cheng CH, Pan SL, Yang PM, Lin DY, Lee KH. Gene expression signature-based approach identifies antifungal drug ciclopirox as a novel inhibitor of HMGA2 in colorectal cancer. *Biomolecules*. 2019;9(11):688. doi:10.3390/biom9110688
- Chen RX, Chen X, Xia LP, et al. N(6)-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. *Nat Commun*. 2019;10(1):4695. doi:10.1038/s41467-019-12651-2
- Zeng Z, Zhao G, Rao C, et al. Knockdown of lncRNA ZFAS1-suppressed non-small cell lung cancer progression via targeting the miR-150-5p/HMGA2 signaling. *J Cell Biochem*. 2019. doi:10.1002/jcb.2954
- Han S, Han B, Li Z, Sun D. Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression. *Cell Cycle*. 2019;18(19):2524–2537. doi:10.1080/15384101.2019.1652035
- Titov SE, Ivanov MK, Demenkov PS, et al. Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears. *BMC Cancer*. 2019;19(1):1010. doi:10.1186/s12885-019-6154-7
- Guo Z, He C, Yang F, Qin L, Lu X, Wu J. Long non-coding RNA-NEAT1, a sponge for miR-98-5p, promotes expression of oncogene HMGA2 in prostate cancer. *Biosci Rep*. 2019;39(9):BSR20190635. doi:10.1042/BSR20190635
- Zhang S, Mo Q, Wang X. Oncological role of HMGA2 (Review). *Int J Oncol*. 2019;55(4):775–788. doi:10.3892/ijo.2019.4856
- Li Q, Wu Q, Li Z, et al. LncRNA LINC00319 is associated with tumorigenesis and poor prognosis in glioma. *Eur J Pharmacol*. 2019;861:172556. doi:10.1016/j.ejphar.2019.172556
- Kong J, Chen X, Wang J, et al. Genetic polymorphisms in the vitamin D pathway and non-small cell lung cancer survival. *Pathol Oncol Res*. 2020;26(3):1709–1715. doi:10.1007/s12253-019-00702-4
- Wang Z, Dai J, Hu N, et al. Identification of new susceptibility loci for gastric non-cardia adenocarcinoma: pooled results from two Chinese genome-wide association studies. *GUT*. 2017;66(4):581–587. doi:10.1136/gutjnl-2015-310612
- Yang Z, Deng Y, Zhang K, et al. LIN28B gene polymorphisms modify hepatoblastoma susceptibility in Chinese children. *J Cancer*. 2020;11(12):3512–3518. doi:10.7150/jca.42798
- Pan J, Zhu J, Wang M, et al. Association of MYC gene polymorphisms with neuroblastoma risk in Chinese children: a four-center case-control study. *J Gene Med*. 2020;22(8):e3190. doi:10.1002/jgm.3190

22. Lu T, Li L, Zhu J, et al. AURKA rs8173 G>C polymorphism decreases wilms tumor risk in Chinese children. *J Oncol*. 2019;2019:9074908. doi:10.1155/2019/9074908
23. De Martino M, Fusco A, Esposito F. HMGA and cancer: a review on patent literatures. *Recent Pat Anticancer Drug Discov*. 2019;14(3):258–267. doi:10.2174/1574892814666190919152001
24. Gong J, Wang Y, Jiang B, Xu B, Hu C. Impact of high-mobility-group A2 overexpression on epithelial-mesenchymal transition in pancreatic cancer. *Cancer Manag Res*. 2019;11:4075–4084. doi:10.2147/CMAR.S199289
25. Mansoori B, Duijf PHG, Mohammadi A, et al. Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. *Expert Opin Ther Targets*. 2020;1–11. doi:10.1080/14728222.2020.1736559
26. Xiao G, Wang X, Yu Y. CXCR4/Let-7a axis regulates metastasis and chemoresistance of pancreatic cancer cells through targeting HMGA2. *Cell Physiol Biochem*. 2017;43(2):840–851. doi:10.1159/000481610
27. Pan Z, Lin J, Wu D, et al. Hsa_circ_0006948 enhances cancer progression and epithelial-mesenchymal transition through the miR-490-3p/HMGA2 axis in esophageal squamous cell carcinoma. *Aging*. 2019;11(24):11937–11954. doi:10.18632/aging.102519
28. Cai X, Nie J, Chen L, Yu F. Circ_0000267 promotes gastric cancer progression via sponging MiR-503-5p and regulating HMGA2 expression. *Mol Genet Genomic Med*. 2020;8(2):e1093. doi:10.1002/mgg3.1093
29. Wang Z, Wang P, Cao L, et al. Long intergenic non-coding RNA 01121 promotes breast cancer cell proliferation, migration, and invasion via the miR-150-5p/HMGA2 axis. *Cancer Manag Res*. 2019;11:10859–10870. doi:10.2147/CMAR.S230367
30. Jiao D, Liu Y, Tian Z. microRNA-493 inhibits tongue squamous cell carcinoma oncogenicity via directly targeting HMGA2. *Oncotargets Ther*. 2019;12:6947–6959. doi:10.2147/OTT.S210567
31. Ma S, Fu T, Zhao S, Gao M. MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. *Eur J Pharmacol*. 2019;852:42–50. doi:10.1016/j.ejphar.2019.03.005
32. Kaur H, Ali SZ, Huey L, et al. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. *Cancer Lett*. 2016;377(1):55–64. doi:10.1016/j.canlet.2016.04.020
33. Liu X, Yidayitula Y, Zhao H, Luo Y, Ma X, Xu M. LncRNA LINC00152 promoted glioblastoma progression through targeting the miR-107 expression. *Environ Sci Pollut Res Int*. 2018;25(18):17674–17681. doi:10.1007/s11356-018-1784-x
34. Liu B, Pang B, Hou X, et al. Expression of high-mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas. *Hum Pathol*. 2014;45(8):1752–1758. doi:10.1016/j.humpath.2014.02.028
35. Zhang S, Zhang H, Yu L. HMGA2 promotes glioma invasion and poor prognosis via a long-range chromatin interaction. *Cancer Med*. 2018;7(7):3226–3239. doi:10.1002/cam4.1534
36. Jia WQ, Zhu JW, Yang CY, et al. Verbascoside inhibits progression of glioblastoma cells by promoting Let-7g-5p and down-regulating HMGA2 via Wnt/beta-catenin signalling blockade. *J Cell Mol Med*. 2020;24(5):2901–2916. doi:10.1111/jcmm.14884
37. Lulli V, Buccarelli M, Ilari R, et al. Mir-370-3p impairs glioblastoma stem-like cell malignancy regulating a complex interplay between HMGA2/HIF1A and the oncogenic long non-coding RNA (lncRNA) NEAT1. *Int J Mol Sci*. 2020;21(10):3610. doi:10.3390/ijms21103610
38. Bouatia-Naji N, Marchand M, Cavalcanti-Proenca C, et al. Smallness for gestational age interacts with high mobility group A2 gene genetic variation to modulate height. *Eur J Endocrinol*. 2009;160(4):557–560. doi:10.1530/EJE-08-0794
39. Takeshita H, Fujihara J, Soejima M, et al. Confirmation that SNPs in the high mobility group-A2 gene (HMGA2) are associated with adult height in the Japanese population; wide-ranging population survey of height-related SNPs in HMGA2. *Electrophoresis*. 2011;32(14):1844–1851. doi:10.1002/elps.201100128
40. Cheng J, Zhuo Z, Yang L, et al. HMGA2 gene polymorphisms and Wilms tumor susceptibility in Chinese children: a four-center case-control study. *Biotechnol Appl Biochem*. 2020;67(6):939–945. doi:10.1002/bab.1857
41. Liu J, Hua RX, Cheng Y, et al. HMGA2 gene rs8756 A>C polymorphism reduces neuroblastoma risk in Chinese Children: a four-center case-control study. *Oncotargets Ther*. 2020;13:465–472. doi:10.2147/OTT.S229975
42. Li L, Zhuo Z, Yang Z, et al. HMGA2 polymorphisms and hepatoblastoma susceptibility: a five-center case-control study. *Pharmacogenomics Pers Med*. 2020;13:51–57. doi:10.2147/PGPM.S241100

Pharmacogenomics and Personalized Medicine

Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed

on the American Chemical Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal>

Dovepress